These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34738211)

  • 21. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of Neovascular Age Macular Degeneration: A Real World Comparison.
    Meira J; Carneiro J; Madeira C; Falcão M; Beato J; Correia S; Falcão-Reis F; Carneiro Â
    Arch Soc Esp Oftalmol (Engl Ed); 2020 Jun; 95(6):263-270. PubMed ID: 32370878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
    Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
    Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; de Jong-Hesse Y; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Jun; 4(6):576-587. PubMed ID: 32107188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.
    Callizo J; Atili A; Striebe NA; Bemme S; Feltgen N; Hoerauf H; Bertelmann T
    Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):913-920. PubMed ID: 30610424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.
    Bakbak B; Ozturk BT; Gonul S; Yilmaz M; Gedik S
    J Ocul Pharmacol Ther; 2013 Oct; 29(8):728-32. PubMed ID: 23848950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
    Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
    Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
    Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
    JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
    Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
    Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM; Costa R; Falcão MS; Barthelmes D; Mendonça LS; Fonseca SL; Gonçalves R; Gonçalves C; Falcão-Reis FM; Soares R
    Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema.
    Hanhart J; Chowers I
    Case Rep Ophthalmol; 2015; 6(1):44-50. PubMed ID: 25802504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
    Eng VA; Rayess N; Nguyen HV; Leng T
    PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
    Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion.
    Azad SV; Salman A; Mahajan D; Sain S; Azad R
    Middle East Afr J Ophthalmol; 2014; 21(4):296-301. PubMed ID: 25371633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.